Source link : https://www.newshealth.biz/health-news/fda-approves-first-menin-inhibitor-for-acute-leukemia/
The FDA granted full approval to the menin inhibitor revumenib (Revuforj) for adults and children 1 year and older with relapsed/refractory acute leukemia and a lysine methyltransferase 2A gene (KMT2A) translocation. Support for the approval came from the phase I/II AUGMENT-101 trial, which evaluated single-agent revumenib in 104 children and adults with previously treated acute […]
Author : News Health
Publish date : 2024-11-15 23:15:01
Copyright for syndicated content belongs to the linked Source.